Please provide your email address to receive an email when new articles are posted on . Guselkumab produced consistent effects among biologic-naïve patients with PsA and those responded inadequately ...
Treatment-naive patients show greater BMD gains taking romosozumab than do patients who had previous antiresorptive treatments. "We conclude that prior antiresorptive therapy, particularly the ...
SAN DIEGO – New research suggests more than one in five “opioid-naïve” patients continue to use the pain medication three months after having a procedure, underscoring the often-overlooked role ...
Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no ...
The effect of dupilumab was investigated among patients with severe and uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Among patients who did or did not undergo surgery to treat their ...
Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting. Real-world survival of men with ...
Healthcare providers need better algorithms to predict opioid dependency, especially among Medicaid patients, according to new research from Stanford University and Gainwell. Stanford researchers ...
AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results